Medexus to Present at The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Investor Conference
Medexus Pharmaceuticals will present at The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Investor Conference, taking place virtually from February 8-11, 2022. The presentation is scheduled for February 8 at 3:00 P.M. Eastern Time, featuring CEO Ken d’Entremont and CFO Marcel Konrad. Medexus focuses on innovative treatments for rare diseases, offering products like Rasuvo™, Metoject®, IXINITY®, and Rupall®. Additionally, their licensed product, Treosulfan, is pending FDA review after its approval in Canada.
- None.
- None.
TORONTO and CHICAGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that it will be presenting at The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Investor Conference being held virtually from Feb 8th to 11th, 2022.
The MicroCap Rodeo’s Winter Wonderland Conference Presentation Details:
Date: Tuesday Feb 8th, 2022
Time: 3:00 P.M. Eastern Time
Ken d’Entremont, Chief Executive Officer, and Marcel Konrad, Chief Financial Officer of Medexus, will present the Company overview and will be hosting virtual one-on-one meetings throughout the conference. Please contact The MicroCap Rodeo to learn more about the event.
About Medexus
Medexus is a leader in innovative rare disease treatment solutions with a strong North American commercial platform and a portfolio of proven best-in-class products. Our current focus is on the therapeutic areas of hematology, auto-immune diseases, and allergy. We continue to build a highly differentiated company with a growing portfolio of innovative and high-value orphan and rare disease products that will underpin our growth for the next decade.
Our current leading products are Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B (a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding); and Rupall®, an innovative prescription allergy medication with a unique mode of action.
We have also licensed Treosulfan, a preparative regimen for allogeneic hematopoietic stem cell transplantation to be used in combination with fludarabine, for commercialization in the United States and Canada. Treosulfan was approved by Health Canada in June 2021 and is marketed in Canada as Trecondyv®. Treosulfan is currently under review by the U.S. Food and Drug Administration.
Our mission is to provide the best healthcare products to healthcare professionals and patients. We strive to deliver on this mission by acting on our core values: Quality, Innovation, Customer Service, and Collaboration.
Contacts
For more information, please contact any of the following:
Medexus
Ken d’Entremont, Chief Executive Officer
Medexus Pharmaceuticals Inc.
Tel: 905-676-0003
Email: ken.dentremont@medexus.com
Marcel Konrad, Chief Financial Officer
Medexus Pharmaceuticals Inc.
Tel: 312-548-3139
Email: marcel.konrad@medexus.com
Investor Relations
Victoria Rutherford
Adelaide Capital
Tel: 1-480-625-5772
Email: victoria@adcap.ca
Forward-Looking Statements
Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements). The words “anticipates”, “believes”, “expects”, “will”, “plans”, “potential”, and similar words or expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Medexus cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include those set out in Medexus’s materials filed with the Canadian securities regulatory authorities from time to time, including Medexus’s most recent annual information form and management’s discussion and analysis; future capital requirements and dilution; intellectual property protection and infringement risks; competition (including potential for generic competition); reliance on key management personnel; Medexus’s ability to implement its business plan; Medexus’s ability to leverage its U.S. and Canadian infrastructure to promote additional growth; regulatory approval by relevant health authorities, including the FDA; product reimbursement by third party payers; litigation or expiry with respect to patents or other intellectual property rights; litigation risk; stock price volatility; government regulation; and potential third party claims. Given these risks, undue reliance should not be placed on these forward-looking statements, which are made only as of the date hereof. Other than as specifically required by law, Medexus undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.
FAQ
When is Medexus Pharmaceuticals presenting at The MicroCap Rodeo conference in 2022?
Who will represent Medexus Pharmaceuticals at the Winter Wonderland conference?
What is Medexus Pharmaceuticals' primary focus in the healthcare market?
Which products are highlighted by Medexus Pharmaceuticals?
What is the status of Treosulfan from Medexus Pharmaceuticals?
